.Attributes Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Point of view requires addition of patients along with MASLD and dimension of liver end results in cardio-- renal-- metabolic trials, when information advise mechanistically probable perks and scientific safety and security-- and also lays out points to consider for test style and also regulative approval.